Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.47 |
| ▸ | MMP3 | P08254 | 3/20 | 0.47 |
| ▸ | Q9HBH1 | 3/20 | 0.41 | |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BMP1 | P13497 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135582 | 0.89 | MMP2 (0.46) | MMP2MMP3PDFMEN1TSHR | |
| SCHEMBL7529199 | 0.88 | MMP2 (0.49) | MMP2MMP3BMP1 | |
| SCHEMBL3320642 | 0.87 | MMP1 (0.39) | FAAHMEN1CYP1A2CYP2C9TSHR | |
| SCHEMBL3320647 | 0.87 | MMP1 (0.39) | FAAHMEN1CYP1A2CYP2C9TSHR | |
| SCHEMBL13333271 | 0.84 | ALDH1A1 (0.48) | MEN1TSHRKMT2AALDH1A1 | |
| SCHEMBL13333341 | 0.83 | KMT2A (0.42) | MMP2MMP3PDFKMT2AALDH1A1 | |
| SCHEMBL14282181 | 0.80 | PDF (0.52) | MMP2MMP3PDF | |
| SCHEMBL14282179 | 0.80 | PDF (0.54) | MMP2MMP3PDF | |
| SCHEMBL3320063 | 0.79 | FAAH (0.43) | FAAH | |
| SCHEMBL13333323 | 0.79 | PDF (0.51) | MMP2MMP3PDF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-7186719-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2007-03-06 | — | — | US | disclosed |
| US-7186719-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | MMP2 1579/4885MMP3 3780/4885PDF 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.